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background:  In the HORIZONS-AMI trial bivalirudin had lower events and bleeding vs. heparin + Gp IIbIIIa, but increased acute stent thrombosis. 
Replacing clopidogrel during PCI with ticagrelor, given its greater potency, could help reduce acute stent thrombosis. We compared the acute 
pharmacodynamic [PD] effects of ticagrelor with clopidogrel, when given with bivalirudin and aspirin. 
methods: The study used a randomized, cross-over design in healthy volunteers (n = 15, 31 ± 8 years). After baseline PD measurements of 
thrombus size (Badimon chamber), platelet P2Y12 reactivity (VerifyNow), ADP-induced whole blood aggregation and coagulation time (CT), subjects 
took ticagrelor 180 mg or clopidogrel 600 mg (both with aspirin 81 mg and standard bivalirudin bolus + 1 hour infusion). At 1 hour and 24 hours 
post dose, all PD tests were repeated. 
results: Reductions in thrombus size from baseline were significantly greater with ticagrelor than with clopidogrel at both 1 hour (56% vs. 35%) 
and 24 hours (34% vs. 19%), p<0.05 for both. Platelet function tests showed similar results (Table 1). Effect of bivalirudin (assessed by CT) was 
equal in both treatments and worn off completely by 24 hours. 
Conclusions: Ticagrelor is faster and more potent in its antithrombotic activity than clopidogrel when given in combination with bivalirudin and 
aspirin. Use of ticagrelor during PCI could help reduce acute stent thrombosis while maintaining the bivalirudin benefits observed in HORIZONS-AMI 
Trial. This needs further testing.
TABLE 1
Baseline 1-hour post dose 24-hour post dose
Ticagrelor Clopidogrel Ticagrelor Clopidogrel Ticagrelor Clopidogrel
Thrombus reduction from baseline - - -56.3% (23)† -35.2% (20)* -34.1% (18)† -18.5% (26)*
VerifyNow PRU 273.6 (59) 270.8 (50)
84.3 (84)†
-69%
220.1 (52)*
-19%
92.9 (75)*
-66%
123.1 (72)*
-55%
ADP aggregation 40.8 (15) 41.9 (14)
14.8 (8)†
-64%
23.5 (10)*
-44%
12.6 (6)*
-69%
11.7 (7)*
-72%
Coagulation Time (sec) 54 (8) 51 (11)
163 (31)*
+203%
174 (33)*
+240%
56 (10)
+4%
54 (9)
+6%
Results are mean (standard deviation) and change from baseline.
* p<0.05 vs. baseline; † p<0.05 vs. baseline and clopidogrel.
